论文部分内容阅读
目的:研究膜联蛋白Ⅱ(annexinⅡ)表达与前列腺癌(PCa)临床病理特征及预后的关系。方法:采用免疫组织化学方法(SP法)检测annexinⅡ在40例前列腺增生症(BPH)和85例PCa标本中的表达情况,统计分析annexinⅡ表达与PCa临床病理特征及预后的关系。结果:annexinⅡ在PCa、BPH表达阳性率分别是62.4%、92.5%,两者差异有统计学意义(P<0.05),annexinⅡ在不同Gleason评分、前列腺特异性抗原(PSA)水平、临床分期、不同危险度PCa中,经统计学分析,它们在各组的差异均有统计学意义(P<0.05),Kaplan-Meier生存曲线分析发现annexinⅡ表达阴性PCa患者的生存率显著低于annexinⅡ表达阳性(P<0.01),预后分析发现annexinⅡ表达阴性性均预示着PCa预后较差(P<0.01)。结论:膜联蛋白Ⅱ表达与PCa的发生、进展及预后有关,可作为PCa诊断的分子标记物及预后判断的独立因子。
Objective: To investigate the relationship between annexin Ⅱ expression and the clinicopathological features and prognosis of prostate cancer (PCa). Methods: The expression of annexin Ⅱ in 40 cases of benign prostatic hyperplasia (BPH) and 85 cases of PCa was detected by immunohistochemical method (SP method). Results: The positive rates of annexin Ⅱ in PCa and BPH were 62.4% and 92.5%, respectively (P <0.05). The differences of annexin Ⅱ between different Gleason scores, PSA levels, clinical stage and different (P <0.05). The Kaplan-Meier survival curve analysis showed that the survival rate of annexin Ⅱ-negative PCa patients was significantly lower than that of annexinⅡ (P <0.05) <0.01). The prognosis analysis showed that the negative annexin Ⅱ expression all indicated the poor prognosis of PCa (P <0.01). Conclusion: The expression of Annexin Ⅱ is related to the occurrence, progression and prognosis of PCa, which may serve as a molecular marker for PCa diagnosis and an independent factor for prognostic judgment.